Content Tagged CYPC219 Subscribe to RSS Feed

Clopidogrel in CYP2C19 poor metabolizers: Four-fold dose increase may be needed

Published: Aug 31st, 2014

Clopidogrel is an antiplatelet agent that is bioactivated through a two-step process involving the polymorphic CYP2C19 enzyme. CYP2C19 genotype can be used to predict clopidogrel response, particularly in patients undergoing […]

Cardiology

Published: Aug 12th, 2014

Following is a digest of pharmacogenomics journal articles pertaining to cardiology. The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most […]

Genetic Testing for Clopidogrel

Published: Aug 1st, 2014

Interventional cardiologists at UF Health order a CYP2C19 genetic test through the UF Health Personalized Medicine Program and UF Health Pathology Laboratories to help determine the right medicine and the […]

CYP2C19 genotype variability: Effects on voriconazole and metabolite levels

Published: Jun 15th, 2014

Teresa Vo, PharmD, 2013-2014 PGY2 Resident in Personalized Medicine In a prospective evaluation of 95 patients treated with voriconazole (Vfend—Pfizer) over a 2-year period, CYP2C19 and CYP2C9 genotypes were not […]

Clopidogrel: CYP2C19, CYP1A2 effects in some post-MI patients

Published: Jun 1st, 2014

Daniel Zambrano (University of Florida College of Pharmacy PharmD Candidate, Class of 2015)   A recent large study showed associations between both loss-of-function and gain-of-function CYP polymorphisms and poor outcomes […]

Preemptive genotyping: More than 90% of patients have actionable result

Published: May 15th, 2014

Out of approximately 10,000 patients genotyped in the Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment (PREDICT) program at Vanderbilt University Medical Center, 91% had at least one actionable […]

CYP2D6 and CYP2C19 variability: Increased antidepressant trials, side effects?

Published: May 7th, 2014

In a retrospective analysis of individuals with obsessive-compulsive disorder (OCD) previously treated with multiple trials of antidepressants, neither CYP2D6 nor CYP2C19 metabolism status was associated with overall differences in duration […]